

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Combadiere et al.

Patent No. 7,151,087

Issued: December 19, 2006

Application No. 10/700,313

Filed: October 31, 2003

Confirmation No. 5461

For: CC CHEMOKINE RECEPTOR 5 DNA,
NEW ANIMAL MODELS AND
THERAPEUTIC AGENTS FOR HIV
INFECTION

**FILED VIA EFS
ON MARCH 21, 2007**

Examiner: John D. Ulm

Art Unit: 1649

Attorney Reference No. 4239-66645-01

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR CERTIFICATE OF CORRECTION

The following printing errors were noted in comparing the printed patent with the papers in the attorneys' files:

On the Cover Sheet:

On page 2 of the cover sheet, under the heading "Other Publications," second column, line 15, "Immunodeficiency" should be --Immunodeficiency--.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 36-38, "Combadiere et al., "Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor," *J. Biol. Chem.* 270:16491-16494 (1995)" should be deleted because it duplicates the citation at second column, lines 21-23.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 39-41, "Feng et al., "HIV-1 Entry Cofactor: Functional cDNA Cloning of

a Seven-Transmembrane, G Protein–Coupled Receptor,” *Science* 272:872-877 (1996)” should be deleted because it duplicates the citation at second column, lines 24-26.

On page 2 of the cover sheet, under the heading “Other Publications,” second column, lines 42-43, “Gong et al., “RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors,” *J. Biol. Chem.* 271:10521-10527 (1996)” should be deleted because it duplicates the citation at second column, lines 27-28.

On page 2 of the cover sheet, under the heading “Other Publications,” second column, lines 44-46, “Rucker et al., “Regions in β -Chemokine Receptors CCR5 and CCR2b that Determine HIV-1 Cofactor Specificity,” *Cell* 87:437-446 (1996)” should be deleted because it duplicates the citation at second column, lines 29-31.

On page 2 of the cover sheet, under the heading “Other Publications,” second column, lines 47-48, “Database PIR2 Accession No. G02653, Dec. 21, 1990 (also referred to as EMBL Accession No. A43113, Jul. 12, 1996)” should be deleted because it duplicates the citation at second column, lines 32-33.

In the Specification:

Column 2, line 44 (specification page 4, line 6), “CC CKCR5” should be --CC CKR5--.

Column 4, line 23 (specification page 7, line 14), “stains” should be --strains--.

Column 5, line 20 (specification page 8, line 28), “FIV” should be --HIV--.

Column 9, line 2 (specification page 14, line 12), “Strathem” should be --Strathern--.

Column 10, line 4 (specification page 15, line 27), “2072” should be --2072)--.

Column 10, lines 13-14 (specification page 16, line 3),
“2-(difluoromethyl)-DL-omithine” should be --2-(difluoromethyl)-DL-ornithine--.

Column 12, line 44 (specification page 19, line 26), “et al” should be --et al.--.

Column 16, line 7 (specification page 24, line 30), “_LV” should be --V_L--.

Column 16, lines 15-16 (specification page 25, line 6), “242:423426” should be --242:423-426--.

Column 16, line 59 (specification page 26, line 6), “HUV” should be --HIV--.

Column 17, line 25 (specification page 26, line 25; 3/14/2006 Amendment), “SEQ ID NO: 4” should be --SEQ ID NO: 5--.

Column 17, line 26 (specification page 26, line 26; 3/14/2006 Amendment), “SEQ ID NO: 5” should be --SEQ ID NO: 6--.

Column 17, line 27 (specification page 26, line 27; 3/14/2006 Amendment), “SEQ ID NO: 6” should be --SEQ ID NO: 7--.

Column 17, line 42 (specification page 27, line 6), “described Merrifield,” should be --described by Merrifield (--.

Column 17, line 59 (specification page 27, lines 16-17), “spectros-copy” should be --spectroscopy--.

Column 19, line 4 (specification page 29, line 5), “Lemer” should be --Lerner--.

Column 19, line 8 (specification page 29, line 8), “HUV-infected” should be --HIV-infected--.

Column 21, lines 10-11 (specification page 32, line 11), the new paragraph on line 11 beginning with “American Pharmaceutical Association” should not be a new paragraph, but should continue the sentence from line 10.

Column 22, line 4 (specification page 33, line 22), “PHARMACEUTICAL SCIENCES” should be -- PHARMACEUTICAL SCIENCES--.

Column 24, line 34 (specification page 37, line 10), “267 25889-25897” should be --267:25889-25897--.

Column 25, line 44 (specification page 39, line 3), “1981)” should be --1981))--.

Column 25, line 56 (specification page 39, line 11), “(Invitrogen (San Diego, Calif.)” should be --(Invitrogen, San Diego, Calif.)--.

Column 27, line 12 (specification page 41, line 10), “components the” should be --components of the--.

Column 27, line 20 (specification page 41, line 15), “ethyl oleate” should be --ethylolate--.

Column 27, line 25 (specification page 41, line 19), “include” should be
--including--.

Column 28, line 4 (specification page 42, line 18), “(1993)” should be --(1993).--.

Column 30, line 62 (specification page 47, line 2), “CDNA” should be --cDNA--.

Column 31, line 41 (specification page 48, line 4), “(1995)” should be --(1995).--.

Column 33, line 25 (specification page 50, line 23), “IC₅₀]-5” should be
--[IC₅₀] ~5--.

Column 33, line 27 (specification page 50, line 25), “IC₅₀S-100 and 200” should
be -- IC₅₀S ~100 and 200--.

Column 33, line 33 (specification page 50, line 28), “IC₅₀-80” should be
--IC₅₀ ~80--.

Column 35, line 28 (specification page 53, line 13; 3/14/2006 Amendment),
“SEQ ID NO: 4” should be --SEQ ID NO: 5--.

Column 35, line 29 (specification page 53, line 14; 3/14/2006 Amendment),
“SEQ ID NO: 5” should be --SEQ ID NO: 6--.

Column 35, line 30 (specification page 53, line 15; 3/14/2006 Amendment),
“SEQ ID NO: 6” should be --SEQ ID NO: 7--.

Column 35, line 35 (specification page 53, line 17), “vaccina-based” should be
--vaccinia-based--.

Column 35, line 65 (specification page 54, line 7), “Sigrna” should be --Sigma--.

Column 36, line 8 (specification page 54, line 13; 3/14/2006 Amendment),
“CCR5306” should be --CCR5₃₀₆--.

Column 36, lines 9-10 (specification page 54, line 15; 3/14/2006 Amendment),
“3) bases” should be --3 bases--.

Column 36, line 10 (specification page 54, line 15; 3/14/2006 Amendment),
“X/io” should be --Xho--.

Column 36, line 46 (specification page 55, line 5), “5494.)” should be --5494)--.

Column 37, line 9 (specification page 55, line 24), “antiserun” should be
--antiserum--.

Column 37, line 18 (specification page 55, line 30), "stras" should be --strains--.

Column 38, line 16 (specification page 56, line 20), "dovnrnodulation" should be --downmodulation--.

Column 38, line 22 (specification page 56, line 22), "cheomkine" should be --chemokine--.

In the Claims:

Column 53, line 28, claim 5 (claim 27, 7/21/2006 Amendment), "The" should be --A--.

Column 54, line 9, claim 5 (claim 27, 7/21/2006 Amendment), "C4" should be --CD4--.


A Certificate of Correction is attached to make formal notice of the errors in the subject patent.

The fee of \$100.00 due under 37 C.F.R. § 1.20(a) is being paid concurrently herewith via EFS. The Director is hereby authorized to charge any additional fees that may be required in connection with filing request for certificate of correction and any extension of time, or credit any overpayment, to Deposit Account No. 02-4550.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 1 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Cover Sheet:

On page 2 of the cover sheet, under the heading "Other Publications," second column, line 15, "Immunodeficiency" should be --Immunodeficiency--.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 36-38, "Combadiere et al., "Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor," *J. Biol. Chem.* 270:16491-16494 (1995)" should be deleted because it duplicates the citation at second column, lines 21-23.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 39-41, "Feng et al., "HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor," *Science* 272:872-877 (1996)" should be deleted because it duplicates the citation at second column, lines 24-26.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 42-43, "Gong et al., "RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors," *J. Biol. Chem.* 271:10521-10527 (1996)" should be deleted because it duplicates the citation at second column, lines 27-28.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 2 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 44-46, "Rucker et al., "Regions in β -Chemokine Receptors CCR5 and CCR2b that Determine HIV-1 Cofactor Specificity," *Cell* 87:437-446 (1996)" should be deleted because it duplicates the citation at second column, lines 29-31.

On page 2 of the cover sheet, under the heading "Other Publications," second column, lines 47-48, "Database PIR2 Accession No. G02653, Dec. 21, 1990 (also referred to as EMBL Accession No. A43113, Jul. 12, 1996)" should be deleted because it duplicates the citation at second column, lines 32-33.

In the Specification:

Column 2, line 44, "CC CKCR5" should be --CC CKR5--.

Column 4, line 23, "stains" should be --strains--.

Column 5, line 20, "FIV" should be --HIV--.

Column 9, line 2, "Strathem" should be --Strathern--.

Column 10, line 4, "2072" should be --2072)--.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 3 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 10, lines 13-14, "2-(difluoromethyl)-DL-omithine" should be --2-(difluoromethyl)-DL-ornithine--.

Column 12, line 44, "et al" should be --et al.--.

Column 16, line 7, "L_LV" should be --V_L--.

Column 16, lines 15-16, "242:423426" should be --242:423-426--.

Column 16, line 59, "HUV" should be --HIV--.

Column 17, line 25, "SEQ ID NO: 4" should be --SEQ ID NO: 5--.

Column 17, line 26, "SEQ ID NO: 5" should be --SEQ ID NO: 6--.

Column 17, line 27, "SEQ ID NO: 6" should be --SEQ ID NO: 7--.

Column 17, line 42, "described Merrifield," should be --described by Merrifield (--.

Column 17, line 59, "spectros-copy" should be --spectroscopy--.

Column 19, line 4, "Lemer" should be --Lerner--.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 4 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 19, line 8, "HUV-infected" should be --HIV-infected--.

Column 21, lines 10-11, the new paragraph on line 11 beginning with "American Pharmaceutical Association" should not be a new paragraph, but should continue the sentence from line 10.

Column 22, line 4, "PHARMACEUTICAL. SCIENCES" should be --PHARMACEUTICAL SCIENCES--.

Column 24, line 34, "267 25889-25897" should be --267:25889-25897--.

Column 25, line 44, "(1981)" should be --(1981))--.

Column 25, line 56, "(Invitrogen (San Diego, Calif.))" should be --(Invitrogen, San Diego, Calif.)--.

Column 27, line 12, "components the" should be --components of the--.

Column 27, line 20, "ethyl oleate" should be --ethyloleate--.

Column 27, line 25, "include" should be --including--.

Column 28, line 4, "(1993)" should be --(1993).--.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 5 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30, line 62, "CDNA" should be --cDNA--.

Column 31, line 41, "(1995)" should be --(1995).--.

Column 33, line 25, "IC₅₀]-5" should be --[IC₅₀] ~5--.

Column 33, line 27, "IC₅₀S-100 and 200" should be -- IC₅₀S ~100 and 200--.

Column 33, line 33, "IC₅₀-80" should be --IC₅₀ ~80--.

Column 35, line 28, "SEQ ID NO: 4" should be --SEQ ID NO: 5--.

Column 35, line 29, "SEQ ID NO: 5" should be --SEQ ID NO: 6--.

Column 35, line 30, "SEQ ID NO: 6" should be --SEQ ID NO: 7--.

Column 35, line 35, "vaccina-based" should be --vaccinia-based--.

Column 35, line 65, "Sigrna" should be --Sigma--.

Column 36, line 8, "CCR5306" should be --CCR5₃₀₆--.

Column 36, lines 9-10, "(3) bases" should be --3 bases--.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 7,151,087

DATED : December 19, 2006

INVENTOR(S) : Combadiere et al.

Page 6 of 6

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 36, line 10, "X/io" should be --Xho--.

Column 36, line 46, "5494.)" should be --5494)--.

Column 37, line 9, "antiserun" should be --antiserum--.

Column 37, line 18, "stras" should be --strains--.

Column 38, line 16, "dovnrnodulation" should be --downmodulation--.

Column 38, line 22, "cheomkine" should be --chemokine--.

In the Claims:

Column 53, line 28, claim 5, "The" should be --A--.

Column 54, line 9, claim 5, "C4" should be --CD4--.

MAILING ADDRESS OF SENDER: Sheree L. Rybak, Ph.D.
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204-2988

PATENT NO. 7,151,087

No. of add'l copies
@ 30¢ per page

⇒ 0